Physician

Raja S Mehdi, MD

According to 2025 Medicare claims, Raja Mehdi, MD (NPI: 1366441743) practices medical oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 89103-4918.

Mehdi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 549 traditional Medicare patients, billed 181,005 HCPCS/CPT codes, and received $3,376,732 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,792 prescription claims across 461 beneficiaries totaling $8,771,250 in drug costs, led by Xtandi (Enzalutamide). DME data shows 76 claims. Open Payments data shows 101 records totaling $9,121. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $503,198 to $3,376,732. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,521,082 to $8,771,250. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	313	100,104	$503,198
2016	327	95,533	$606,632
2017	271	78,758	$811,151
2018	281	98,454	$742,040
2019	349	154,278	$988,663
2020	455	210,619	$2,599,926
2021	459	154,675	$2,257,323
2022	561	162,427	$2,088,774
2023	575	171,888	$2,755,151
2024	549	181,005	$3,376,732

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	108	740	$1,521,082
2016	113	716	$1,257,921
2017	87	504	$551,243
2018	115	585	$571,190
2019	146	702	$879,622
2020	279	1,228	$2,327,544
2021	295	1,148	$2,233,144
2022	353	1,341	$3,715,642
2023	443	1,478	$3,760,803
2024	461	1,792	$8,771,250

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	51	$26,123
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	50	$5,768
2020	N/R	33	$3,016
2021	N/R	39	$6,980
2022	27	99	$3,284
2023	N/R	47	$15,120
2024	13	76	$78,876

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	96	489	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	291	445	$94
M0010	Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services	113	716	$77
96375	Injection of additional new drug or substance into vein	77	470	$11
36415	Insertion of needle into vein for collection of blood sample	297	538	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	144	4,320	$1,775,820
Imbruvica	Ibrutinib	58	1,624	$925,813
Ibrance	Palbociclib	54	1,512	$839,135
Revlimid	Lenalidomide	40	1,008	$662,632
Kisqali	Ribociclib Succinate	45	1,253	$653,805

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8705	Topotecan, oral, 0.25 mg	N	N/R	12	$77,529
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$600
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	13	29	$546
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	90	$2,409	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$6,712	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raja S. Mehdi, MD?

Tedicare shows public-source Medicare data for Raja S. Mehdi, MD (NPI 1366441743), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raja S. Mehdi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Raja S. Mehdi, MD?

Raja S. Mehdi, MD is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Raja S. Mehdi, MD have Open Payments data?

Raja S. Mehdi, MD has 101 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.